A clinical forum brought together pulmonologists and advanced practice providers to share their experiences navigating the changing COPD and asthma landscape.
The Evolving Landscape of Targeted Therapy in Asthma and COPD Care in 2026
A clinical forum focuses on how advanced practice providers (APP) and clinicians are now navigating how to translate emerging data into real-world practice.
Experts weigh new biologics including dupilumab, tezepelumab, and depemokimab, and how eosinophils guide real-world prescribing.
New biologics transform severe asthma and COPD, yet prednisone overuse persists—see practical selection tips and outpatient steroid stewardship gaps.
Clinicians compare newest asthma/COPD biologics, highlighting dupilumab’s edge, biomarker shifts, and insurance barriers shaping real-world use.
Experts unpack new asthma/COPD biologics, eosinophil+FeNO targeting, twice-yearly depemokimab switching, and payer hurdles in 2026 care.
A clinical forum discussed referral dynamics, access barriers, and patient health literacy challenges that shape biologic use in the real world.
Advertisement
Advertisement
Trending on HCPLive
1
ACHIEVE-5: Orforglipron Improves Glycemic Control, Weight in T2D on Basal Insulin
2
VESALIUS-CV: Evolocumab Reduces Cardiovascular Events in Patients With High-Risk Diabetes
3
GLP-1 Discontinuation Cuts Chances of Meeting Weight Loss, Glycemic Goals in T2D
4
Survodutide Shows Fat Mass Loss, Liver Fat Reductions in Patients With Obesity Without T2D
5